Labdane diterpenoids from the ripe fruits of Forsythia suspensa and their anti-inflammatory activities in vitro

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-09-25 DOI:10.1016/j.phytol.2025.103042

Yue Wang , Jia-Huan Liu , Xi-Dian Yue , De-Wu Zhang , Sheng-Jun Dai

引用次数: 0

Abstract

One previously unreported labdane diterpenoid with a rare 15,12-olide moiety, named forsypenanhuin A (1), along with four known ones (2-5), were isolated from the fruits of Forsythia suspensa. The structure and relative configuration of the undescribed compound were elucidated via extensive spectroscopic methods, and its absolute configuration was fully confirmed by single crystal X-ray diffraction analysis using Cu Kα radiation. In vitro, five labdane diterpenoids exhibited significant anti-inflammatory activities due to inhibiting the release of TNF-α, IL-6, and IL-1β in the LPS-induced RAW264.7 cells.

查看原文本刊更多论文

连翘果实中二萜类化合物的体外抗炎活性研究

从连翘（forsysythia suspensa）的果实中分离出一种先前未报道的含有罕见的15,12-olide片段的labdane二萜，命名为forsypenanhuin a(1)，以及四种已知的二萜（2-5）。用广谱分析方法对化合物的结构和相对构型进行了表征，用Cu Kα辐射单晶x射线衍射分析完全证实了化合物的绝对构型。在体外实验中，5种labdane二萜通过抑制lps诱导的RAW264.7细胞中TNF-α、IL-6和IL-1β的释放而表现出显著的抗炎活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.